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Summary. Cord blood samples from 2020 unrelated newborns 
were screened for levels of enzyme activity for twelve en- 
zymes. The level of enzymatic activity for 100 determinations 
were consistent with the existence of an enzyme-deficiency al- 
lele. The frequency of deficiency alleles in the Black popula- 
tion (0.0071) was four times higher (after removal of the 
G6PD*A- variant) than in the Caucasian sample (0.0016). 
These frequencies are approximately double the frequency of 
rare electrophoretic mobility variants at similar loci in the 
same population. Given the number of functionally important 
loci in the human genome, these enzyme deficiency variants 
could constitute a significant health burden. 
Introduction 
Increasing evidence is accumulating that the genome of each 
individual may be functionally hemizygous at from several to 
many autosomal loci, in addition to the loci located on the sex 
chromosome. That is, one member of the allelic pair at an au- 
tosomal locus is either absent (molecular hemizygosity) or is 
unable to direct the synthesis of functional gene product (bio- 
chemical hemizygosity). The level of hemizygosity in the 
human genome has a direct impact on the frequency of both 
genetic disease and reproductive failure (Carter 1977, 1982; 
Neel 1979; Vogel 1984; Costa et al. 1985). Hemizygosity also 
has a direct effect on the estimated health cost of mutational 
damage in that a functionally significant mutation at a hemi- 
zygous locus would appear to be inherited as a dominant trait 
and would be of significance in the first generation (Mohren- 
weiser 1983; Searle and Edwards 1986). 
Examples of hemizygosity that have received recent atten- 
tion are the several heritable tumors that are associated with a 
predisposing event involving the apparent absence of genetic 
material (Cavenee et al. 1986; Seizinger et al. 1986). That is, 
the individual is apparently hemizygous at a locus associated 
with tumor development and therefore a single somatic event 
is sufficient to initiate tumorogenesis. Molecular hemizygosity 
in the genome, identified with Southern blotting techniques 
and not associated with disease conditions, has also been iden- 
tified. These known hemizygous segments include regions ad- 
jacent to several defined genes (Bell et al. 1980; Rotwein et al. 
1983), variation in the number of copies of genes (Erickson 
and Schmickel 1985), and variation in the copy number of re- 
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petitive elements (Jeffrey et al. 1985). Molecular studies of a 
series of genetic diseases outline the range of events, consid- 
ered as "point mutations", which at the physiological/meta- 
bolic level of cellular function appear to be null alleles. These 
events range from the complete or partial deletion of a gene 
(Monaco et al. 1986; Rozen et al. 1985; Spritz and Forget 
1983; Yang et al. 1984) to seemingly innocuous base substitu- 
tions (Busslinger et al. 1981; Daar et al. 1986; Spritz et al. 
1981). Although the frequency of hemizygosity at any single 
locus associated with a genetic disease or a genetic predisposi- 
tion to a disease appears to be small, it would appear that the 
total hemizygosity in the genome may be significant when 
summed across the estimated 50-100,000 expressed loci of the 
human genome (Office of Technology Assessment 1986). 
Within the context of the development of a program to 
study the germinal mutation rate in human populations (Neel 
et al. 1987), we have now examined erythrocyte samples from 
2020 unrelated newborns, including those from previous re- 
ports (Mohrenweiser 1981, 1983), for the presence of a level 
of enzyme activity consistent with the existence of an enzyme 
deficiency allele at twelve erythrocyte enzyme loci. Data from 
similar studies in other populations will be reviewed in order 
to estimate the apparent level of detectable hemizygosity as 
manifested by a specific reduction in enzyme activity for a set 
of loci encoding enzyme proteins. The data will be contrasted 
with the frequency of rare electrophoretic mobility variants in 
the same populations. 
Materials and methods 
Umbilical cord blood samples were obtained from newborns 
at the University of Michigan Women's Hospital. Informed 
consent and blood samples were obtained from parents; the 
samples were stored in liquid nitrogen (Neel et al. 1979). 
Adenylate kinase (AK, EC 2.7.4.3); aspartate aminotrans- 
ferase (GOTS, EC 2.3.1.1); enolase (ENO, EC 1.2.1.11); 
phosphoglyceromutase (DPGM, EC 2.7.5.3); glyceraldehyde- 
3-phosphate dehydrogenase (GAPD, EC 1.2.1.12); glucose- 
phosphate isomerase (GPI, EC 5.3.1.9); glucose-6-phosphate 
dehydrogenase (G6PD, EC 1.1.1.49); lactate dehydrogenase 
(LDH-B, EC 1.1.1.27); malate dehydrogenase (MDH, EC 
1.1.1.37); phosphoglycerate kinase (PGK, EC 2.7.2.3); pyru- 
vate kinase (PK, EC 2.7.1.40); and triosephosphate isomerase 
(TPI, EC 5.3.1.1) assays were performed as described by 
Fielek and Mohrenweiser (1979), Mohrenweiser (1983), and 
Mohrenweiser and Fielek (1982). The stability characteristics 
of each enzyme as well as the influence of reticulocyte per- 
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Table 1. Distribution and frequency of erythrocyte-enzyme-deficiency variants among loci in unselected newborns 
Enzyme Number of occurrences 
Caucasian Black 
Normal activity (%) Normal activity (%) 
<50 50-55 56-60 61-65 Variants/ <50 50-55 56-60 61-65 Variants/ 
(< 10) a (10- (16- (21- deter- (< 10) a (i0- (16- (21- deter- 





AK 0 0 0 2 2/1714 0 0 0 0 0/168 3/1988 
DPGM 0 1 0 1 2/1087 0 0 0 0 0/ 85 3/1236 
ENO 2 3 0 1 6/1094 1 0 0 0 1/ 85 1011246 
GAPDH 0 0 0 0 0/1035 0 0 0 0 0/ 84 0/1183 
GOTS 0 0 1 1 211592 0 0 0 1 1/161 3/1854 
GPI 2 1 0 1 4/1712 0 0 0 0 0/168 4/1986 
LDH 0 0 0 0 0/1736 0 0 0 0 0/170 0/2013 
MDH 0 1 0 0 1/1736 0 0 0 1 1/170 2/2013 
PGK 0 0 0 0 0/1736 0 0 0 0 0/170 0/2013 
PK 1 4 2 11 18/1736 0 0 0 4 4/170 23/20;13 
TPI 2 1 3 3 9/1713 1 0 1 5 7/168 17/1987 
G6PD (Female) 6 3 1 0 10/ 821 4 2 0 2 8/ 71 19/ 952 
G6PD (Male) 0 0 2 i 3/ 908 9 3 0 0 12/ 97 16/1052 
G6PD (Total) 13°/1729 20d/168 35c'd/2004 
Total 57/18,620 34/1767 100121,536 
a Activity for sex linked trait 
b Total includes about 100 probands that could not be assigned to the other two ethnic groups 
c Includes one mobility variant, G6PD*CAA1 
a Includes 11 variants with G6PD*A- mobility 
centage and mean cell age on the level of enzyme activity in 
both adult and cord blood samples have been described (Moh- 
renweiser et al. 1981). Only the first-born child in any family 
has been included in the current sample, in contrast to the re- 
port on mutation rates in this population by Neel et al. (1987) 
where, with the exception of identical twins, all newborns 
were included. Approximately 3%-4% of the probands were 
considered premature (birth weight < 2000 g) or exhibited a 
congenital defect (Neel and Mohrenweiser 1984). 
Results 
Functional null or enzyme-deficiency variants were defined by 
a level of enzymatic activity that was less than 65% of the nor- 
mal or control mean activity and concurrently, a value at least 
3 standard deviations (SD) below the population mean 
(Mohrenweiser 1981). The latter constraint has proven to be 
redundant in that the coefficient of variation among individu- 
als within the newborn or the adult population is less than 
12% for each of the twelve enzymes included in the study and 
therefore 65% of control is always more than three SDs from 
the mean (Mohrenweiser 1983). In addition, for the reduced 
activity to be classified as the result of an enzyme-deficiency 
allele, the activity of other enzymes assayed in this individual 
sample must be within the normal range. Thus, abnormal re- 
suits associated with generalized hemoglobinopathies or other 
traits not involving a specific enzyme locus would be excluded 
from further consideration. This requirement of a normal 
level of activity for other erythrocyte enzymes also serves as a 
control for sample quality. Only a single example of a proband 
with two deficiency alleles was observed. This male child in- 
herited the TPI deficiency allele from the father and the 
G6PDA- allele from his mother. 
The results from screening samples from 1740 Caucasian 
and 172 Black unrelated newborns are shown in Table 1. The 
total group includes additional individuals from other races 
(1%) as well as individuals of mixed or unknown racial origins 
(4%). In 100 of the 21,536 determinations, the level of en- 
zymatic activity was consistent with the existence of an en- 
zyme-deficiency variant. A genetic basis for the reduced activ- 
ity was confirmed for each variant by the detection of a re- 
duced level of enzyme activity in erythrocytes from one of the 
parents. Fifty-seven of the variants were identified among 
18,620 determinations (3.1 variants per 1000 determinations) 
from Caucasian newborns while 34 variants were detected 
among 1767 determinations (19.2 variants per 1000 determi- 
nations) from Black newborns. 
Enzyme-deficiency variants were detected in this study at 
nine of the twelve loci screened. Deficiencies at the other 
three loci have been identified in other studies and have been 
reported in the clinical literature. An LDHB null variant has 
been identified as a polymorphism in a Central American In- 
dian population (Tanis et al. 1977; Mohrenweiser and Novot- 
ny 1982); while deficiencies of PGK and GAPDH as well as 
LDH have been reported, although they are less frequent 
than many of the other enzymopathies (Beutler 1978; Kahn et 
al. 1979). Thus, it is probable that the absence of deficiency 
variants at these three loci, in this study, reflects the frequen- 
cies of the deficiency alleles in the population studied in Ann 
Arbor rather than a failure of the analytical procedures. 
The range of residual activity in the probands (with the ex- 
ception of males with G6PD deficiency) ranged from 44%- 
64% of normal and from 3.3 to 5.4 SDs below the mean. In all 
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families, one parent had a level of enzyme activity consistent 
with the profile observed in the proband. The affected parents 
were evenly distributed between mothers and fathers. Thus, 
the marked reduction in enzyme activity had characteristics of 
a recessively (or sex-linked, in the case of G6PD deficiency) 
inherited genetic trait. The specificity of the reduction, that is, 
restriction to a specific enzyme, and codominant inheritance 
would be consistent with the existence of a molecular lesion 
involving the structural gene or the immediate flanking re- 
gions for the enzyme exhibiting the reduced activity. In gen- 
eral, genetic variation that does not involve the structural 
locus would not usually be inherited as a codominant trait, as 
are the nonsex-linked traits observed in this study. 
The frequency of enzyme-deficiency alleles in the Cauca- 
sian sample is 0.00161 while the frequency in the Black sample 
is about six times higher, namely 0.01010. The relatively high 
frequency of G6PD deficiencies in Blacks and PK deficiencies 
in Caucasians is consistent with the clinical data on en- 
zymopathies and the frequency of the G6PG*A- variant in the 
Black population (Beutler 1979; Motulsky and Yoshida 1969). 
Of the 20 G6PD deficiencies in Blacks, 11 were associated with 
the electrophoretically detectable A-  allele. Excluding these 
11 variants from the deficiency class reduces the frequency of 
such variants to 0.0071 in the Black group, a frequency still 
more than four times the frequency in the Caucasian group. 
One of the G6PD deficiencies in the Caucasian group was as- 
sociated with a variant with C-like electrophoretic mobility. 
With the exception of the above mentioned G6PD mobility 
variants, none of the other deficiency variants were associated 
with an identifiable alteration in electrophoretic mobility. The 
existence of a weakly staining mobility variant would be con- 
sistent with the deficiency being associated with an unstable 
enzyme molecule, as is known for the G6PD*A- variant. The 
absence of detectable mobility variation does not exclude an 
unstable enzyme molecule as the cause of the deficiency. The 
interchanged amino acids may have had similar charges or the 
residual enzyme activity may have been too low to be detected 
following electrophoresis, especially in the heterozygote indi- 
vidual. Failure to produce a recognizable gene product or the 
existence of an inactive enzyme subunit are other possible 
explanations for the absence of detectable functional gene 
product. 
As previously noted in preliminary reports from this new- 
born screen, the high frequency of the TPI-deficiency allele, 
especially among Blacks, was surprising (Mohrenweiser 1983; 
Mohrenweiser and Fielek 1982). Reports of homozygosity for 
TPI deficiency in the clinical literature are relatively rare with 
only about thirty reported cases in the world including only 
four individuals in three families in the U.S. (Maquat et al. 
1985; Mohrenweiser and Fielek 1982; Rosa et al. 1985). This 
contrasts with the expected frequency of at least 1 in 2000 
Black newborns, given that the deficiency allele frequency is 
0.023 in this population. No homozygous deficient probands 
were observed in this study, as expected given the number of 
Black newborns screened. Because of the severity of the 
symptoms, the homozygous deficient individuals should be 
observed in clinical studies if they survive to birth. Studies of 
TPI-deficient mice indicate that homozygosity for several dif- 
ferent TPI null alleles is apparently an embryo lethal condi- 
tion, in that no homozygous deficient animals are observed 
(Charles and Pretsch 1987). Given the apparent lethality of 
the homozygous condition and the calculation that TPI is the 
least rate-limiting step in glycolysis (Albery and Knowles 
1976), it is difficult to identify a mechanism for the mainte- 
nance of this allele frequency. 
A direct comparison of the relative frequency of deficiency 
and mobility variants can be made at nine loci (excluding 
DPGM, PK, and GAPD,  which were not studied for mobility 
variants). In the Caucasian sample, the frequency of alleles 
for enzyme deficiencies at these nine loci was 0.00169 com- 
pared to an allele frequency of 0.00083 (35 variants/42,111 al- 
leles) for rare mobility variants at the same loci (Mohren- 
weiser et al. 1987). Similar figures in the Black sample were 
0.0078 for deficiency alleles (excluding G 6 P D * X )  and 
0.00088 (3 variants/3395 alleles) for rare electrophoretic mo- 
bility alleles (G6PD*A is a polymorphic variant and therefore 
is excluded as a rare variant in the Black sample). Data are 
available on the frequency of alleles for rare electrophoretic 
mobility variants at forty erythrocyte enzyme loci in these 
populations, the frequencies being 0.00056 for Caucasians 
and 0.00159 for Blacks. Thus, the frequency of deficiency 
variants was 100%-250% greater than the frequency of rare 
electrophoretic mobility variants, irrespective of the data 
base of electrophoretic mobility variants used for the compari- 
son. 
Discussion 
Three other studies of human populations have employed 
similar techniques to screen for enzyme-deficiency alleles. 
Eber et al. (1984) and Krietsch et al. (1977) studying only 5 
erythrocyte enzymes, reported seven variants in about 3000 
individuals (0.5 variants/1000 determinations) in Germany. 
The null-allele frequency (recalculated from their data using 
65% of normal as the definition for a deficiency variant) is 
0.00028. They also identified additional individuals with lesser 
degrees of activity reduction, which are not included in the 
above frequency calculation but which had characteristics con- 
sistent with a heritable genetic trait. Satoh et al. (1983) in 
Japan, studying 11 enzymes, found 61 enzyme-deficiency var- 
iants in 26,634 determinations (2.3 variants/1000 determina- 
tions) for an enzyme-deficiency-allele frequency of 0.00131. 
Mohrenweiser and Neel (1984) detected 11 enzyme-deficiency 
variants in 6741 determinations (1.6 variants/1000 determina- 
tions) among samples from several Amerindian tribes. Com- 
bining these data with the two data bases from this study, one 
obtains an overall unweighted mean frequency of 0.00396 for 
enzyme-deficiency alleles for the five populations. 
The apparent differences among ethnic or geographical 
groups in the frequency of enzyme-deficiency variants reflect, 
at least in part, differences in the battery of loci studied in the 
different populations (low figure for Germany), but they also 
suggest possible ethnic differences (high value for U.S. 
Blacks). The frequencies observed in the study in Germany 
are similar to the frequencies at the same loci in the other 
populations, with the exception of the TPI deficiency in 
Blacks. The higher frequency of deficiency variants among 
Blacks is similar to a higher frequency of mobility variants ob- 
served in this same population (Neel and Mohrenweiser 1987; 
Mohrenweiser et al., in preparation). The distribution of defi- 
ciency variants (excluding G6PDA-) among loci is similar in 
the Black and Caucasian groups with G6PD, TPI, and PK ac- 
counting for 70% and 60% of the variants. The estimates of 
the frequency of enzyme-deficiency variants are not inconsis- 
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tent with estimated frequencies obtained for other loci from 
other studies (Martin 1983; Gershowitz 1983). 
Similar null-variant frequencies have also been observed in 
other species. Voelker et al. (1980a) and Langley et al. (1981) 
have reported frequencies of 2.6 and 2.3 null variants/1000 de- 
terminations in two natural populations of Drosophila 
melanogaster. Bulfield et al. (1984) identified 3.69 low-activity 
variants/1000 determinations in screening wild-caught mice 
(Mus musculus). 
Results from several experiments suggest that de novo mu- 
tations associated with enzyme deficiency are at least as fre- 
quent as mobility mutants. In a study of the spontaneous mu- 
tation rate in Drosophila, null mutants occurred at a rate at 
least three times the rate for mobility mutants (Mukai and 
Cockerham 1977; Voelker et al. 1980b). Null mutants have 
been detected with a frequency similar to that of electropho- 
retic mobility mutants in the offspring of mice exposed to 
chemical mutagens (Lewis and Johnson 1983, 1986; Charles 
and Pretsch 1987). The exception to this generalization, of an 
approximately equal frequency of null and mobility mutants, 
is the results from two radiation mutagenesis studies in mice, 
where all seven of the mutations were nulls (Malling and Val- 
covic 1977; Charles and Pretsch 1986). Racine et al. (1980) 
also reported an increased null-mutation frequency in the 
progeny of irradiated Drosophila. 
The biochemical basis for the deficiency variants will gen- 
erally be either (a) the absence of a protein, (b) the presence 
of a nonfunctional enzyme, or (c) the altered stability of the 
enzyme. As the erythrocyte is unable to synthesize protein, 
the reduced stability of an enzyme molecule is a significant 
cause of erythrocyte enzymopathies although it does not often 
cause a significant metabolic block in nucleated cells. 
The molecular basis for the null variants can range from 
deletion of the entire allele through single base deletions, 
which could result in removal of important regulatory se- 
quences and mRNA processing sites to frameshifts. They 
could also result from point mutations that alter regulatory se- 
quences or processing sites or result in amino acid substitu- 
tions causing enzyme instability, inappropriate processing, or 
the synthesis of a nonfunctional enzyme molecule (Mohren- 
weiser 1983). This spectrum of events that can give rise to en- 
zyme-deficiency variants contrasts with the situation for mo- 
bility variants, which are almost exclusively associated with 
nucleotide substitutions in exons, which therefore give rise to 
the interchange of amino acids with nonidentical charge. 
Assuming that this estimate of the enzyme-deficiency al- 
lele frequency is typical of the average for the remainder of 
the human genome, one can begin to estimate the total level 
of hemizygosity. With a deficiency-allele frequency of 0.00396, 
the frequency of homozygosity at any locus is 1.56 × 10 -5. Esti- 
mates of the number of loci in the human genome generally 
range from 50 to 100,000. Thus, each individual could be 
hemizygous at 200-400 loci in addition to loci located on the 
X chromosome. Assuming that 5000 of these autosomal loci 
are critical for codominantly inherited traits, such that the ab- 
sence of a functional gene product is associated with disease, 
then each conceptuses would be hemizygous at 20 critical loci. 
With these same assumptions, 7% of conceptions would be 
homozygous at a critical locus. It is possible that 5%-10% of 
the spontaneous abortions [estimated at 50% of conceptions 
(Edmonds et al. 1982; Miller et al. 1980) and 30% of the rec- 
ognized spontaneous abortions being due to detectable chro- 
mosomal anomalies] could be associated with homozygosity 
for functionally significant enzyme-deficiency variants. This 
fetal loss plus the diseases associated with single-gene defects 
constitute a significant health burden for the human popula- 
tion (Neel 1979). Additionally, this background level of hemi- 
zygosity increases the potential health burden of new muta- 
tions. A portion of the de novo null mutations will exhibit 
characteristics of a dominant trait since a single event at a 
locus that is constitutively hemizygous will be manifested in 
the first generation (Mohrenweiser 1983; Searle and Edwards 
1986). This contrasts with the usual expectation that "point" 
or "gene" mutations will only have heterozygous and limited 
genetic health consequences for many generations (Denniston 
1982; Carter 1982). 
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